Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.
2.
3.
4.
5.

Role of renal epithelial cells in the initiation of calcium oxalate stones.

Khan SR.

Nephron Exp Nephrol. 2004;98(2):e55-60. Review.

PMID:
15499208
6.

Gallotannin suppresses calcium oxalate crystal binding and oxalate-induced oxidative stress in renal epithelial cells.

Lee HJ, Jeong SJ, Park MN, Linnes M, Han HJ, Kim JH, Lieske JC, Kim SH.

Biol Pharm Bull. 2012;35(4):539-44.

7.

Biomimetic Randall's plaque as an in vitro model system for studying the role of acidic biopolymers in idiopathic stone formation.

Chidambaram A, Rodriguez D, Khan S, Gower L.

Urolithiasis. 2015 Jan;43 Suppl 1:77-92. doi: 10.1007/s00240-014-0704-x. Epub 2014 Aug 15.

8.

Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.

Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F; CLU Working Group.

Arch Ital Urol Androl. 2015 Jul 7;87(2):105-20. doi: 10.4081/aiua.2015.2.105. Review. Erratum in: Arch Ital Urol Androl. 2016 Mar;88(1):76. Ferraro, Manuel [added].

9.

Association of Randall plaque with collagen fibers and membrane vesicles.

Khan SR, Rodriguez DE, Gower LB, Monga M.

J Urol. 2012 Mar;187(3):1094-100. doi: 10.1016/j.juro.2011.10.125. Epub 2012 Jan 21.

11.

Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis.

Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA.

J Urol. 2002 Sep;168(3):1173-81.

PMID:
12187263
12.

Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys.

Yoshioka I, Tsujihata M, Akanae W, Nonomura N, Okuyama A.

Urology. 2011 Apr;77(4):1007.e9-1007.e14. doi: 10.1016/j.urology.2010.11.019. Epub 2011 Jan 22.

PMID:
21256551
14.

Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone.

Evan AP, Lingeman JE, Coe FL, Worcester EM.

Semin Nephrol. 2008 Mar;28(2):111-9. doi: 10.1016/j.semnephrol.2008.01.004. Review.

15.

Animal models of kidney stone formation: an analysis.

Khan SR.

World J Urol. 1997;15(4):236-43. Review.

PMID:
9280052
16.

Calcium oxalate stone disease: role of lipid peroxidation and antioxidants.

Selvam R.

Urol Res. 2002 Mar;30(1):35-47. Review.

PMID:
11942324
17.

The role of Randall plaques on kidney stone formation.

Chung HJ.

Transl Androl Urol. 2014 Sep;3(3):251-4. doi: 10.3978/j.issn.2223-4683.2014.07.03. Review.

18.

Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals.

Khan SR, Thamilselvan S.

Mol Urol. 2000 Winter;4(4):305-12. Review.

PMID:
11156696
19.

Effects of apocynin and losartan treatment on renal oxidative stress in a rat model of calcium oxalate nephrolithiasis.

Li CY, Deng YL, Sun BH.

Int Urol Nephrol. 2009 Dec;41(4):823-33. doi: 10.1007/s11255-009-9534-0. Epub 2009 Feb 25.

PMID:
19241135
20.

Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice.

Evan AP, Weinman EJ, Wu XR, Lingeman JE, Worcester EM, Coe FL.

Urol Res. 2010 Dec;38(6):439-52. doi: 10.1007/s00240-010-0330-1. Epub 2010 Nov 10.

Supplemental Content

Support Center